在耐火性多发性髓瘤中进行顺序BCMA CAR-T细胞疗法
Tim Richardson1, Udo Holtick1, Jan Hendrik Frenking2
1Department I of Internal Medicine, Medical Faculty and University Hospital of Cologne, University of Cologne, Germany.
Blood advances
|July 11, 2025
概括
使用两种不同的BCMA向产品的顺序化学抗原受体T细胞 (CAR-T) 治疗对于复发性多发性髓瘤 (MM) 是安全有效的. 对初始CAR-T的长时间反应预测了第二次CAR-T输液的持久结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 在BCMA导向的CAR-T治疗后多发性髓瘤 (MM) 复发是一个重大的临床挑战.
- 关于重新使用针对相同抗原的CAR-T药物的疗效和安全性的数据有限.
研究的目的:
- 评估BCMA指导的顺序CAR-T治疗在重度预治疗的MM患者中的安全性和有效性.
- 为了确定对第二次CAR-T输液反应的预测因素.
主要方法:
- 在三个医疗中心对10名MM患者进行了现实世界分析,他们接受了ide-cel,随后接受了cilta-cel (第二次CAR-T输液).
- 允许在CAR-T疗法之间进行桥梁治疗.
- 对安全性,反应率和无进展生存率的评估.
主要成果:
- 连续的BCMA导向CAR-T疗法是安全的,没有增加的毒性.
- 实现了100%非常好的部分响应 (VGPR) 率,其中60%实现了MRD阴性.
- 估计的6个月无进展生存率为64.8%.
- 对第一个CAR-T疗法的反应持续时间预测了对第二个CAR-T产品的持续反应.
- BCMA抗原的损失并不常见.
结论:
- 两个不同的BCMA导向CAR-T产品的连续管理在MM中是可行的和有效的.
- 这种方法为初始CAR-T治疗后复发的患者提供了可行的治疗选择.
- 对一线CAR-T治疗的长时间反应是连续CAR-T治疗持续受益的关键因素.
相关概念视频
Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)

